Symmetry Revises 2009 Guidance

updated: 10/26/2009 12:57:18 PM

Symmetry Revises 2009 Guidance

InsideINdianaBusines.com Report

Warsaw-based Symmetry Medical Inc. (NYSE: SMA) is adjusting its 2009 guidance downward. The company says lower than anticipated demand for its orthopaedic and non-orthopaedic markets has prompted it to revise its guidance from the range of $385 million to $405 million, to $355 million to $365 million. Chief Executive Officer Brian Moore says the anticipated drop in orders will result in a significant shortfall of revenue and earnings per share.

Source: Inside INdiana Business

Continued Below...

 
 
<a href="ad_click.asp?ID=1954&url=http%3A%2F%2Fwww%2Epurdueresearchpark%2Ecom" target="new"><img src="images/ads/" border=0 width="300" height="250"></a>
 

Studio(i) Videos

Phil Ray, Omni Severin Indianapolis, General Manager

Omni Severin Indianapolis General Manager Phil Ray talks to Inside INdia...Watch

Jonathan Weinzapfel, Mayor of Evansville

In a Studio(i) interview with Inside INdiana Business Host Gerry Dick, W...Watch

Mike Peduto, Partner, Circle City Tickets

In a Studio(i) interview, Peduto talked about the demand for Colts ticke...Watch

Features

Press Release

WARSAW, Ind., Oct. 26 -- Symmetry Medical Inc. (NYSE:SMA) , a leading independent provider of products to the global orthopaedic device industry and other medical markets, announced today updated full year 2009 financial guidance.

Based on recent diminished order flow resulting from lower than anticipated customer demand for the remainder of 2009, in both orthopaedic and non-orthopaedic markets, Symmetry is adjusting its previously stated annual revenue guidance to a range of $355 million to $365 million, from $385 million to $405 million. The Company has been and will continue to engage in significant cost reduction measures in response to this reduced demand. While these efforts moderate the full impact of lower revenue, the Company now expects full year 2009 earnings per share to be in the range of $0.63 to $0.68 per diluted share, as opposed to the previously announced range of $0.77 to $0.85.


Brian Moore, President and Chief Executive Officer of Symmetry Medical, stated, "In anticipation of a softer overall orthopaedic market in the second half of 2009, we had previously guided for a decrease in revenue and proactively implemented cost adjustments to maintain our earnings goals. Since our previous guidance announcement, and particularly in recent weeks, we have experienced greater than anticipated order reductions. We believe this change in order flow will result in a significant shortfall to our revenue and earnings per share, primarily in the fourth quarter."


Mr. Moore continued, "Despite this recent volatility across all segments of the business, we are encouraged by gains in market share we have realized as our customers consolidate suppliers and focus on assuring product quality and supplier stability. Our customers' recent quarterly results highlight their inventory utilization. While this created negative implications for our business in the near term, it should bode well for Symmetry in the future. In addition, our customers have placed a much renewed emphasis on supply chain management and have engaged us in discussions on our contribution to this process. We see these expanding relationships resulting in a mid to long term positive impact on our business."


About Symmetry Medical Inc.


Symmetry Medical Inc. is a leading independent provider of implants and related instruments and cases to the orthopaedic device industry. The Company also designs, develops and produces these products for companies in other segments of the medical device market, including arthroscopy, dental, laparoscopy, osteobiologic and endoscopy sectors and provides limited specialized products and services to non-healthcare markets, such as the aerospace market.


Source: Symmetry Medical Inc.

  • Print
  • E-Mail
  • Newsletters
 
 

Web Site Design and Development by BitWise Solutions, Inc.